Abstract:Background: Resistance to the currently available classes of antimicrobials has emerged as a major health concern, with a growing number of isolated organisms demonstrating resistance to available antimicrobials. With the escalation of carbapenem resistance, the use of polymyxin B/E (colistin) has increased over the years, which has, in turn, contributed to the worldwide emergence of colistin resistance. The available data on colistin resistance from Southeast Asian nations, including India, is limited, especially in intensive care unit (ICU) settings. The primary objective of our study was to analyze the clinical profile of patients with polymyxin B/E (colistin) resistant positive cultures and to study their outcome in terms of length of ICU stay and outcome at discharge. Materials and methods: This observational, single-center, prospective study was conducted in a 20-bed adult ICU serving both medical and surgical patients at a 1,600-bed tertiary care institute in northern India between Jan 2020 and Dec 2021. In this study, all adult patients, defined as individuals older than 18 years of age, admitted to our ICU with cultures detecting polymyxin B/E (colistin) resistant organisms were included as cases, and all adult ICU patients (age >18 years) with polymyxin B/E (colistin) sensitive cultures were taken as controls. Clinical, laboratory, and demographic parameters, along with ICU variables like severity of illness, length of ICU stay, mechanical ventilation, days of shock, renal replacement therapy (RRT), etc., and outcome at discharge were collected. Identification of resistance to colistin and minimal inhibitory concentration (MIC) of colistin is based on Clinical and Laboratory Standards Institute (CLSI) guidelines. For statistical analysis, Mann-Whitney U test, Fisher's exact test, and binary logistic regression were used. Results: Twenty-eight cases and 55 controls (n = 83) were included for analysis. Abdominal [gastrointestinal (GI)] sepsis was the most common diagnosis (41.8%) at admission to the ICU, and Klebsiella pneumoniae was the most common species isolated in both the cases (96.4%) and the controls (50.9%). The most common site of isolation of Gram-negative bacteria in both cases and controls was blood (71.4 vs 74.5%), followed by deep-seated pus (21.4 vs 23.64%). The most common class of drugs to which the cases were sensitive was tetracyclines in 60.7%, followed by ceftazidime-avibactam. Factors such as prior exposure to colistin, exposure to monobactams in the ICU, and ICU stay in days were identified as independent predictors for colistin resistance. Overall mortality was not statistically different between cases and controls (p -value 0.38). Conclusion: Factors like prolonged ICU stay, exposure to monobactams in the ICU, and a history of prior exposure to colistin in the previous 90 days are independent predictors of colistin resistance. The most common organism to develop colistin resistance identified was K. pneumoniae, and the most common site of isolation was blood. There was no difference in mortality between colistin-resistant and colistin-sensitive patients.

Treating a patient with pan-resistant Acinetobacter: a case study

Pan-resistant Acinetobacter infection in neonates in Karachi, Pakistan

A case of treatment for pulmonary infection caused by multidrug-resistant Acinetobacter baumannii

Retrospective Analysis of Antimicrobial Resistance Trends in Pseudomonas aeruginosa and Acinetobacter baumannii

PP-017 First Report in China of a Human Infection by Alphaproteobacteria Using Shell Vial Culture

Investigation of antibiotic resistance and biofilm formation ability of Acinetobacter baumannii isolated from urinary catheters

[Clinical characteristics and therapy of pan-drug resistant Acinetobacter baumannii infection].

ESKAPE Pathogens: Antimicrobial Resistance Patterns, Risk Factors, and Outcomes a Retrospective Cross-Sectional Study of Hospitalized Patients in Palestine

Acinetobacter: an old friend, but a new enemy

Acinetobacter baumannii producing ESBLs and carbapenemases in the Intensive Care Units developing fosfomycin and colistin resistance

Prevalence and Antibiotic Susceptibility Pattern of Bacterial Pathogens in Intensive Care Unit (ICU) of a Tertiary Care Facility

Portrait of a killer: Uncovering resistance mechanisms and global spread of Acinetobacter baumannii

Efficacy of different antibiotics in management of pan-drug-resistant Acinetobacter baumannii infection in ICU

Combinations of Antibiotics Effective against Extensively- and Pandrug-Resistant Acinetobacter baumannii Patient Isolates

Periodic phenotypic profile analysis of Acinetobacter baumannii drug resistance characteristics showing the emergence of PDR

Emerging Colistin Resistance: Experience from an Intensive Care Unit of a Tertiary Care Center in India

Current Therapeutic Approaches for Multidrug-Resistant and Extensively Drug-Resistant Acinetobacter baumannii Infections

Molecular Analysis of Carbapenem and Aminoglycoside Resistance Genes in Carbapenem-Resistant Pseudomonas aeruginosa Clinical Strains: A Challenge for Tertiary Care Hospitals

Clinical Presentations and Outcomes of Post-Operative Central Nervous System Infection Caused by Multi-Drug-Resistant/Extensively Drug-Resistant Acinetobacter baumannii : A Retrospective Study.

Antimicrobial resistance of Pseudomonas aeruginosa: navigating clinical impacts, current resistance trends, and innovations in breaking therapies

Frequency and Antimicrobial Susceptibility Profile of Acinetobacter baumannii Isolated at a Tertiary Care Diagnostic Facility